Acetazolamide for metabolic alkalosis complicating respiratory failure with chronic obstructive pulmonary disease or obesity hypoventilation syndrome: a systematic review

Conclusion Acetazolamide may have little impact on respiratory failure with metabolic alkalosis in patients with chronic respiratory diseases. However, clinically significant benefits or harms are unable to be excluded, and larger trials are required. PROSPERO registration number CRD42021278757.

http://thorax.bmj.com/cgi/content/short/78/10/1004?rss=1

Source: Thorax - September 15, 2023 Category: Respiratory Medicine Authors: Bemand, T. J., Chatoor, R., Natale, P., Strippoli, G., Delaney, A. Tags: Thorax Critical care Source Type: research